Research programme: protein-protein interaction inhibitors - Priaxon/Ludwig-Maximilians-University

Drug Profile

Research programme: protein-protein interaction inhibitors - Priaxon/Ludwig-Maximilians-University

Latest Information Update: 23 Jul 2013

Price : $50

At a glance

  • Originator Priaxon
  • Developer Ludwig-Maximilians-University; Priaxon
  • Class Small molecules
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 08 Jul 2013 Early research in Cancer in Germany (unspecified route)
  • 08 Jul 2013 Priaxon and Ludwig-Maximillians-University receive grant from Bavarian Research Foundation for development of inhibitors of protein-protein interactions in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top